Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Cancer Chemother Pharmacol ; 85(6): 1097-1108, 2020 06.
Article in English | MEDLINE | ID: mdl-32449143

ABSTRACT

PURPOSE: Brusatol, a natural quassinoid that is isolated from a traditional Chinese herbal medicine known as Bruceae Fructus, possesses biological activity in various types of human cancers, but its effects in nasopharyngeal carcinoma (NPC) have not been reported. This study aimed to explore the effect and molecular mechanism of brusatol in NPC in vivo and in vitro. METHODS: The antiproliferative effect of brusatol was assessed by MTT and colony formation assays. Apoptosis was determined by flow cytometry. The expression of mitochondrial apoptosis, cell cycle arrest, and Akt/mTOR pathway proteins were determined by western blot analysis. Further in vivo confirmation was performed in a nude mouse model. RESULTS: Brusatol showed antiproliferative activity against four human NPC cell lines (CNE-1, CNE-2, 5-8F, and 6-10B) in a dose-dependent manner. This antiproliferative effect was accompanied by mitochondrial apoptosis and cell cycle arrest through the modulation of several key molecular targets, such as Bcl-xl, Bcl-2, Bad, Bax, PARP, Caspase-9, Caspase-7, Caspase-3, Cdc25c, Cyclin B1, Cdc2 p34, and Cyclin D1. In addition, we found that brusatol inhibited the activation of Akt, mTOR, 4EBP1, and S6K, suggesting that the Akt/mTOR pathway is a key underlying mechanism by which brusatol inhibits growth and promotes apoptosis. Further in vivo nude mouse models proved that brusatol significantly inhibited the growth of CNE-1 xenografts with no significant toxicity. CONCLUSIONS: These observations indicate that brusatol is a promising antitumor drug candidate or a supplement to current chemotherapeutic therapies to treat NPC.


Subject(s)
Antineoplastic Agents/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , Nasopharyngeal Carcinoma/drug therapy , Nasopharyngeal Neoplasms/drug therapy , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Quassins/pharmacology , TOR Serine-Threonine Kinases/antagonists & inhibitors , Animals , Apoptosis , Biomarkers, Tumor , Cell Movement , Cell Proliferation , Humans , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Nasopharyngeal Carcinoma/metabolism , Nasopharyngeal Carcinoma/pathology , Nasopharyngeal Neoplasms/metabolism , Nasopharyngeal Neoplasms/pathology , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
3.
Ophthalmology ; 125(4): 559-568, 2018 04.
Article in English | MEDLINE | ID: mdl-29096998

ABSTRACT

PURPOSE: Age-related macular degeneration (AMD), a multifactorial disease with variable phenotypic presentation, was associated with 52 single nucleotide polymorphisms (SNPs) at 34 loci in a genome-wide association study (GWAS). These genetic variants could modulate different biological pathways involved in AMD, contributing to phenotypic variability. To better understand the effects of these SNPs, we performed a deep phenotype association study (DeePAS) in the Age-Related Eye Disease Study 2 (AREDS2), followed by replication using AREDS participants, to identify genotype associations with AMD and non-AMD ocular and systemic phenotypes. DESIGN: Cohort study. PARTICIPANTS: AREDS and AREDS2 participants. METHODS: AREDS2 participants (discovery cohort) had detailed phenotyping for AMD; other eye conditions; cardiovascular, neurologic, gastrointestinal, and endocrine disease; cognitive function; serum nutrient levels; and others (total of 139 AMD and non-AMD phenotypes). Genotypes of the 52 GWAS SNPs were obtained. The DeePAS was performed by correlating the 52 SNPs to all phenotypes using logistic and linear regression models. Associations that reached Bonferroni-corrected statistical significance were replicated in AREDS. MAIN OUTCOME MEASURES: Genotype-phenotype associations. RESULTS: A total of 1776 AREDS2 participants had 5 years follow-up; 1435 AREDS participants had 10 years. The DeePAS revealed a significant association of the rs3750846 SNP at the ARMS2/HTRA1 locus with subretinal/sub-retinal pigment epithelial (RPE) hemorrhage related to neovascular AMD (odds ratio 1.55 [95% confidence interval 1.31-1.84], P = 2.67 × 10-7). This novel association remained significant after conditioning on participants with neovascular AMD (P = 2.42 × 10-4). Carriers of rs3750846 had poorer visual acuity during follow-up (P = 6.82 × 10-7) and were more likely to have a first-degree relative with AMD (P = 5.38 × 10-6). Two SNPs at the CFH locus, rs10922109 and rs570618, were associated with the drusen area in the Early Treatment Diabetic Retinopathy Study Report (ETDRS) grid (P = 2.29 × 10-11 and P = 3.20 × 10-9, respectively) and the center subfield (P = 1.24 × 10-9 and P = 6.68 × 10-8, respectively). SNP rs570618 was additionally associated with the presence of calcified drusen (P = 5.38 × 10-6). Except for positive family history of AMD with rs3750846, all genotype-phenotype associations were significantly replicated in AREDS. No pleiotropic associations were identified. CONCLUSIONS: The association of the SNP at the ARMS2/HTRA1 locus with subretinal/sub-RPE hemorrhage and poorer visual acuity and of SNPs at the CFH locus with drusen area may provide new insights in pathophysiological pathways underlying different stages of AMD.


Subject(s)
High-Temperature Requirement A Serine Peptidase 1/genetics , Macular Degeneration/genetics , Polymorphism, Single Nucleotide , Proteins/genetics , Aged , Cohort Studies , Complement Factor H/genetics , Double-Blind Method , Drug Combinations , Fatty Acids, Omega-3/therapeutic use , Female , Follow-Up Studies , Genetic Association Studies , Genome-Wide Association Study , Humans , Lutein/therapeutic use , Macular Degeneration/diagnosis , Macular Degeneration/drug therapy , Male , Retinal Drusen/diagnosis , Retinal Drusen/drug therapy , Retinal Drusen/genetics , Retinal Hemorrhage/diagnosis , Retinal Hemorrhage/drug therapy , Retinal Hemorrhage/genetics , Retinal Pigment Epithelium/pathology , Visual Acuity/physiology , Zeaxanthins/therapeutic use
4.
J Ethnopharmacol ; 195: 173-181, 2017 Jan 04.
Article in English | MEDLINE | ID: mdl-27845267

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Kuntai capsule, a traditional Chinese medicine, has been widely used for the clinical treatment of menopausal syndrome. However, its mechanisms remain poorly understood. Considering that aging ovaries are the primary cause of menopause, this study was designed to investigate the effects and mechanisms of Kuntai capsule on ovarian function in a novel mice model with accelerated aging ovaries. MATERIALS AND METHODS: Seventy-five female C57BL/6 mice were chosen for this study. Fifteen of the mice were separated into the normal control group (NC). The remaining sixty were used to establish the novel accelerated aging ovary model by superovulation and oxidative stress and then by randomly dividing the mice into four equal groups. One group was considered the model group (Mod). The other three groups were treated with low (0.4g/kg), middle (0.8g/kg) and high (1.6g/kg) doses of Kuntai capsule intragastrically every day for 4 weeks. During the treatment, the body weight and fur condition of all mice were recorded. All the mice were forced to swim to record their exhaustive swimming time (EST), which measures their strength. Mice were then sacrificed for sampling. Ovarian reserve was evaluated using follicle counts and AMH expression. Ovarian function was evaluated using estrous cycle, sex hormone level and litter experiments. Ovarian follicles were categorized and counted to estimate ovarian reserve, and ovarian histologic sections were stained for terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) to detect apoptotic cells. The ultrastructure of ovarian cells was observed using transmission electron microscopy. Western blotting was used to measure expression of Bax, Bcl2, AMH and SOD2 protein. RESULTS: Compared with the NC GROUP, the Mod group clearly displayed worse fur condition and ovarian function. These situations showed some improvement after Kuntai capsule treatment. Specifically, the fur condition and the EST of the Kuntai capsule groups were superior to the fur condition and EST of the Mod group. In cases of damaged ovarian function, Kuntai capsule can regulate the estrous cycles, increase hormone secretion and fertility and significantly decrease atretic follicles. The transmission electron microscopy results revealed that Kuntai capsule rescued the ovarian ultrastructure of mice. TUNEL staining confirmed that the apoptotic cells were reduced after Kuntai capsule treatment. Western blotting revealed that Kuntai capsule can increase AMH, SOD2, and Bcl2 protein expression and decrease Bax expression. CONCLUSIONS: Kuntai capsule may improve damaged ovarian function, which may be related to its antioxidant and anti-apoptosis effects.


Subject(s)
Antioxidants/pharmacology , Drugs, Chinese Herbal/pharmacology , Ovarian Reserve/drug effects , Ovary/drug effects , Oxidative Stress/drug effects , Administration, Oral , Age Factors , Animals , Anti-Mullerian Hormone/metabolism , Antioxidants/administration & dosage , Apoptosis/drug effects , Capsules , Cytoprotection , Dose-Response Relationship, Drug , Drugs, Chinese Herbal/administration & dosage , Estrous Cycle/drug effects , Female , Fertility/drug effects , Inhalation Exposure , Mice, Inbred C57BL , Muscle Strength , Organ Size , Ovarian Follicle/drug effects , Ovarian Follicle/ultrastructure , Ovary/metabolism , Ovary/physiopathology , Ovary/ultrastructure , Ozone/toxicity , Pregnancy , Proto-Oncogene Proteins c-bcl-2/metabolism , Superovulation , Superoxide Dismutase/metabolism , Time Factors , bcl-2-Associated X Protein/metabolism
5.
Sci Rep ; 6: 28278, 2016 06 21.
Article in English | MEDLINE | ID: mdl-27325186

ABSTRACT

The role of pathological response in long-term outcome is still unclear in cervical cancer patients treated with neoadjuvant chemotherapy (NACT) in China. This study aimed to investigate the effect of optimal pathologic response (OPR) on survival in the patients treated with NACT and radical hysterectomy. First, 853 patients with stage IB2-IIB cervical cancer were included in a retrospective analysis; a Cox proportional hazards model was used to investigate the relationship between pathological response and disease-free survival (DFS). In the retrospective database, 64 (7.5%) patients were found to have achieved an OPR (residual disease <3 mm stromal invasion); in the multivariate Cox model, the risk of death was much greater in the non-OPR group than in the OPR group (HR, 2.61; 95%CI, 1.06 to 6.45; P = 0.037). Next, the role of OPR was also evaluated in a prospective cohort of 603 patients with cervical cancer. In the prospective cohort, 56 (9.3%) patients were found to have achieved an OPR; the log-rank tests showed that the risk of recurrence was higher in the non-OPR patients than in the OPR group (P = 0.05). After combined analysis, OPR in cervical cancer was found to be an independent prognostic factor for DFS.


Subject(s)
Antineoplastic Agents/therapeutic use , Neoplasms, Squamous Cell/drug therapy , Platinum Compounds/therapeutic use , Uterine Cervical Neoplasms/drug therapy , Adult , Aged , Chemotherapy, Adjuvant , Disease-Free Survival , Female , Humans , Hysterectomy , Kaplan-Meier Estimate , Lymphatic Metastasis , Middle Aged , Neoadjuvant Therapy , Neoplasm Staging , Neoplasms, Squamous Cell/mortality , Neoplasms, Squamous Cell/secondary , Proportional Hazards Models , Prospective Studies , Retrospective Studies , Treatment Outcome , Uterine Cervical Neoplasms/mortality , Uterine Cervical Neoplasms/pathology , Young Adult
6.
J Biomed Nanotechnol ; 11(4): 600-12, 2015 Apr.
Article in English | MEDLINE | ID: mdl-26310067

ABSTRACT

A hydrophilic indocyanine green derivative (ICG-Der-02) was covalently doped into mesoporous silica-coated gold nanorods (AuNRs/mSiO2). The self-synthesized derivative offers one carboxyl functional group on a side chain, which enables ICG-Der-02 to be covalently linked to nanomaterials and reduces the probability of leakage/desorption of the dye. The detection of infrared luminescence around 1270 nm confirmed that 102 is efficiently generated by the nanocomposite (AuNRs/mSiO2-ICG-Der-02). Furthermore, a second layer of silica was coated onto the nanocomposite, which then was conjugated with the α(v) integrin-targeting cyclic peptide (RGD-4C). The cell tests showed that the resulting nanoconjugate (AuNRs/mSiO2-ICG-Der-02/RGD-4C) was able to bind preferentially to HT-1080 human fibrosarcoma cells. Due to the synergistic effect of the produced nanoconjugates, a dual-modality photothermal and photochemical therapy was successfully achieved by 808 nm irradiation. Compared to using photothermal or photochemical therapy alone, the dual-modality photothermal/photochemical therapeutic strategy proved to be more damaging to HT-1080 cells and enhanced the effectiveness of photodestruction. Our work presents a novel approach to the multimodal treatment of fibrosarcoma and shows promise for future use in cancer theranostics.


Subject(s)
Fibrosarcoma/therapy , Gold/chemistry , Indocyanine Green/chemistry , Metal Nanoparticles/chemistry , Nanotubes/chemistry , Phototherapy/methods , Cell Line, Tumor , Flow Cytometry , Humans , Lasers , Magnetic Resonance Spectroscopy , Microscopy, Electron, Transmission , Nanomedicine/methods , Reproducibility of Results , Singlet Oxygen/chemistry , Spectrometry, Fluorescence , Spectroscopy, Fourier Transform Infrared
7.
Guang Pu Xue Yu Guang Pu Fen Xi ; 32(12): 3295-8, 2012 Dec.
Article in Chinese | MEDLINE | ID: mdl-23427555

ABSTRACT

A method for indirectly determining the molybdenum in Chinese herbal medicine by butanol extraction and dilute hydrochloric acid dissolution was established for atomic fluorescence spectrometry. The molybdoarsenate heteropoly acid, formed in the presence of As(V) and ammonium molybdate in 0.3 mol x L(-1) sulphuric acid medium, was separated and enriched in the organic solvent, then the evaporation of organic reagent was implemented and the left residue was dissolved in dilute hydrochloric acid in which the arsenic content was determined on behalf of molybdenum. In the optimum experimental conditions, molybdenum content in 0-15 microg x L(-1) range depicts a good linear relationship, the detection limit and relative standard deviation of 0.44 microg x L(-1) and 1.1% were obtained, respectively. Spiked Chinese herbal medicine samples were determined with the proposed method, and recoveries of 95.6%-101.3% were achieved.


Subject(s)
Drugs, Chinese Herbal/chemistry , Molybdenum/analysis , Spectrometry, Fluorescence/methods , Spectrophotometry, Atomic/methods , Butanols/chemistry , Hydrochloric Acid/chemistry , Solvents/chemistry
8.
Atherosclerosis ; 189(1): 133-41, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16469322

ABSTRACT

Low folate/high homocysteine (Hcy) is an established risk marker for cardiovascular disease (CVD). Some in vivo studies suggest low folate may independently contribute to CVD. To study the effects of mild folate deficiency on endothelial function, we adapted the EA.hy 926 endothelial cell line to growth in medium containing 23 nM folic acid (LO cells) or 9 microM folic acid (HI cells). Folate derivatives were substantially depleted in LO cells relative to HI cells. No differences were seen in intracellular homocysteine, S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), the SAM:SAH ratio, or global DNA methylation, and there was no consistent difference in secreted homocysteine. A greater percentage of LO than HI cells were in S phase of the cell cycle; supplementation of LO cells with thymidine/hypoxanthine prevented this. LO cells were more elongated than HI cells and did not form tight monolayers. Stress fibers were very prominent in LO but not HI cells. Treatment of LO cells with rho kinase inhibitors abolished stress fibers and partially normalized cell shape. LO cell monolayers were more permeable than HI cell monolayers at confluence, and MCP-1 mRNA and protein expression was higher in LO than HI cells. Our results suggest that mild folate deficiency is proatherosclerotic.


Subject(s)
Atherosclerosis/etiology , Endothelium, Vascular/metabolism , Folic Acid Deficiency/complications , Atherosclerosis/metabolism , Atherosclerosis/pathology , Cell Division , Cell Line , Chemokine CCL2/genetics , Chemokine CCL2/metabolism , DNA Methylation , Endothelium, Vascular/pathology , Folic Acid Deficiency/metabolism , Folic Acid Deficiency/pathology , Gene Expression , Humans , Phenotype , RNA/genetics , Reverse Transcriptase Polymerase Chain Reaction , Risk Factors , S-Adenosylhomocysteine/metabolism , S-Adenosylmethionine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL